Description: Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.
Home Page: www.pharming.com
Darwinweg 24
Leiden,
2333 CR
Netherlands
Phone:
31 71 524 7400
Officers
| Name | Title |
|---|---|
| Dr. Sijmen de Vries M.B.A., M.D., MBA | Pres, CEO & Exec. Director |
| Dr. Bruno M. L. Giannetti | Consultant |
| Mr. Jeroen Wakkerman | Chief Financial Officer |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer |
| Susanne Embleton | Investor Relations Mang. |
| Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer |
| Mr. Anurag Relan | Chief Medical Officer |
| Mr. Stephen Toor | Chief Commercial Officer & GM of Americas |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 151.5152 |
|---|---|
| Trailing PE: | 24.4 |
| Price-to-Book MRQ: | 3.9421 |
| Price-to-Sales TTM: | 3.6871 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 277 |